Technical Analysis for ARWR - Arrowhead Research Corporation

Grade Last Price % Change Price Change
D 20.24 -1.17% -0.24
ARWR closed down 1.17 percent on Friday, February 7, 2025, on 63 percent of normal volume. It ran into resistance at its 50 day moving average. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation.
3 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Up

Date Alert Name Type % Chg
50 DMA Resistance Bearish 0.00%
Bearish Engulfing Bearish 0.00%
Shooting Star Candlestick Bearish 0.00%
Lizard Bearish Bearish Day Trade Setup 0.00%
Upper Bollinger Band Touch Strength 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -1.17%
NR7 Range Contraction -1.17%
Multiple of Ten Bullish Other -1.17%
Up 3 Days in a Row Strength -1.17%
Earnings Movers Other -0.15%

   Recent Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Arrowhead Research Corporation Description

Arrowhead Research Corporation operates as a clinical stage therapeutics company. It has development programs in oncology, obesity, and chronic hepatitis B virus (HBV) infection. The company assembles a set of technologies, including Dynamic Polyconjugate platform, a RNA delivery system that addresses multiple organ systems and cell types, promotes multi-log gene knockdown in rodents and non-human primates, and induces endosomal escape; and RONDEL, a RNA delivery system for systemic siRNA delivery, and RNAi-mediated mRNA and protein knockdown in human melanoma patients. It also offers Homing Peptides platform, a library of short peptides for the development of peptide-drug conjugates and companion diagnostics. The company's principal product candidates include Adipotide, an anti-obesity peptide, which is in Phase I clinical trial for disrupting the blood supply that supports unhealthy fat by the targeted induction of apoptosis (cell death) in the vasculature of adipose tissue; ARC-520, an RNAi-based therapeutic to treat chronic HBV infection; and CALAA-01, an RNAi-based therapeutic that has completed a Phase IB clinical trial, which targets solid tumors. Its products also comprise CRLX-101 for NSC lung cancer; and Tubulin Inhibitor for oncology. The company, formerly known as InterActive Group, Inc., was founded in 2003 and is headquartered in Pasadena, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Solid Tumors Organ Systems Molecular Biology Infection Obesity Hepatitis B Gene Expression RNA Rna Interference Apoptosis Chronic Hbv Infection Chronic Hepatitis B Virus Rna Therapeutics Si RNA Small Interfering Rna

Is ARWR a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Comments

Indicators

Indicator Value
52 Week High 36.72
52 Week Low 17.05
Average Volume 2,229,518
200-Day Moving Average 22.61
50-Day Moving Average 20.79
20-Day Moving Average 19.72
10-Day Moving Average 19.98
Average True Range 1.10
RSI (14) 51.69
ADX 14.35
+DI 29.78
-DI 17.00
Chandelier Exit (Long, 3 ATRs) 18.55
Chandelier Exit (Short, 3 ATRs) 21.04
Upper Bollinger Bands 21.35
Lower Bollinger Band 18.09
Percent B (%b) 0.66
BandWidth 16.53
MACD Line -0.01
MACD Signal Line -0.10
MACD Histogram 0.0968
Fundamentals Value
Market Cap 2.53 Billion
Num Shares 125 Million
EPS -4.94
Price-to-Earnings (P/E) Ratio -4.10
Price-to-Sales 130.37
Price-to-Book 13.81
PEG Ratio -1.32
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 22.79
Resistance 3 (R3) 23.04 22.44 22.37
Resistance 2 (R2) 22.44 21.79 22.32 22.22
Resistance 1 (R1) 21.34 21.39 21.04 21.09 22.08
Pivot Point 20.74 20.74 20.59 20.62 20.74
Support 1 (S1) 19.64 20.09 19.34 19.39 18.40
Support 2 (S2) 19.04 19.69 18.92 18.26
Support 3 (S3) 17.94 19.04 18.12
Support 4 (S4) 17.69